Medications for Bipolar Disorder
Mood Stabilizers
Lithium and valproate are the cornerstone mood stabilizers for bipolar disorder, with lithium showing superior long-term efficacy and unique anti-suicide effects. 1
- Lithium is FDA-approved for both acute mania and maintenance therapy in patients age 12 and older, with response rates of 38-62% in acute mania 1
- Lithium reduces suicide attempts 8.6-fold and completed suicides 9-fold, an effect independent of its mood-stabilizing properties 1
- Target lithium levels are 0.8-1.2 mEq/L for acute treatment and 0.6-1.0 mEq/L for maintenance 1
- Valproate (divalproex) shows higher response rates (53%) compared to lithium (38%) in children and adolescents with mania and mixed episodes 1
- Valproate is particularly effective for mixed or dysphoric mania, with therapeutic blood levels of 50-100 μg/mL 1, 2
- Lamotrigine is approved for maintenance therapy and is particularly effective for preventing depressive episodes in bipolar disorder 1, 3
- Carbamazepine is a second-line mood stabilizer alternative when lithium and valproate fail or are contraindicated 1, 2
Atypical Antipsychotics
Atypical antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone) are approved for acute mania in adults and provide rapid symptom control. 1
- Quetiapine is recommended as first-line treatment for bipolar depression, both as monotherapy and as adjunctive treatment 3, 4
- Quetiapine plus valproate is more effective than valproate alone for adolescent mania 1
- Olanzapine is effective at 5-20 mg/day for acute mania, and the combination of olanzapine plus fluoxetine is FDA-approved for bipolar depression 1, 5, 3
- Olanzapine 10-20 mg/day combined with lithium or valproate is superior to mood stabilizers alone for acute mania 5
- Aripiprazole (5-15 mg/day) has a favorable metabolic profile compared to olanzapine and is recommended for acute mania 1, 4
- Risperidone in combination with lithium or valproate is effective for acute mania, with a typical target dose of 2 mg/day 1, 6
- Lurasidone and cariprazine are newer options approved for bipolar depression and acute mania respectively 3, 4
- Asenapine is another atypical antipsychotic option for acute mania 1, 4
Antidepressants
Antidepressants should never be used as monotherapy in bipolar disorder due to risk of mood destabilization and must always be combined with a mood stabilizer. 1
- The olanzapine-fluoxetine combination is the only FDA-approved antidepressant regimen specifically for bipolar depression 1, 5
- When adding antidepressants for bipolar depression, SSRIs (particularly fluoxetine) or bupropion are preferred over tricyclic antidepressants 1, 3, 2
- Antidepressants should be tapered 2-6 months after remission to prevent mood destabilization 2
- Antidepressant monotherapy can trigger manic episodes or rapid cycling 1
Combination Therapy Strategies
Combination therapy with a mood stabilizer plus an atypical antipsychotic provides superior efficacy compared to monotherapy for severe presentations and treatment-resistant cases. 1
- The combination of lithium or valproate plus an atypical antipsychotic is recommended for severe acute mania 1
- Lithium plus valproate combination serves as the foundation to which other medications can be added if needed 2
- Maintenance therapy should continue for at least 12-24 months after mood stabilization, with some patients requiring lifelong treatment 1, 4
Monitoring Requirements
- For lithium: Monitor lithium levels, renal function (BUN, creatinine), thyroid function (TSH), and urinalysis every 3-6 months 1
- For valproate: Monitor serum drug levels, hepatic function, and hematological indices every 3-6 months 1
- For atypical antipsychotics: Monitor BMI monthly for 3 months then quarterly, and blood pressure, fasting glucose, and lipids at 3 months then yearly 1
Common Pitfalls
- Inadequate duration of maintenance therapy leads to relapse rates exceeding 90% in noncompliant patients versus 37.5% in compliant patients 1
- Withdrawal of lithium dramatically increases relapse risk, especially within 6 months following discontinuation 1
- Failure to monitor for metabolic side effects of atypical antipsychotics, particularly weight gain and dyslipidemia 1, 5
- Using antidepressants without a mood stabilizer can precipitate mania or rapid cycling 1